ACTRN12614000731695
Recruiting
Phase 1
A Phase I Study to Evaluate the Safety and Efficacy of Mesenchymal Stromal Cells (MSC) for Treating Chronic Obstructive Pulmonary Disease (COPD)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- COPD
- Sponsor
- Royal Perth Hospital
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Moderate to severe COPD (GOLD 2\-3\)
Exclusion Criteria
- •Inability to give consent
- •Cardiac failure
- •Renal failure
- •Liver failure
- •Active cancer
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
DCB-DM101 in Participants with Type 2 Diabetes MellitusACTRN12618001140246VitNovo Australia Pty Ltd24
Active, not recruiting
Phase 1
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)Small Cell Lung CancerJPRN-jRCT2031220086Tagashira Shuzo50
Recruiting
Phase 1
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapyExtensive Stage Small Cell Lung CancerJPRN-jRCT2031220277Tagashira Shuzo340
Not yet recruiting
Not Applicable
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung CancerNL-OMON53561Amgen4
Recruiting
Phase 1
Safety and Efficacy of MagSense Human Epidermal Growth Factor Receptor 2 (HER2) Test Reagent in Breast Cancer Lymph Node Magnetic Reasonance Imaging (MRI) and Magnetic Relaxometry (MRX).Breast CancerCancer - BreastACTRN12621000126819Imagion Biosystems, Ltd30